Form 144 VERTEX PHARMACEUTICALS Filed by: Bozic Carmen

Fri, 05 Jun 2026 14:33:00 -0400

si-local-file:///var/storage/secattach/20260605/26610505.html

Form 144 VERTEX PHARMACEUTICALS Filed by: Bozic Carmen

Fri, 05 Jun 2026 14:33:00 -0400

si-local-file:///var/storage/secattach/20260605/26610505.html

Vertex presents positive data for ALYFTREK in young cystic fibrosis patients

Fri, 05 Jun 2026 12:05:12 -0400

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) presented clinical data showing that 65% of children ages 2 to 5 with cystic fibrosis achieved sweat chloride levels below 30 mmol/L when treated with ALYFTREK, according to data presented at the European Cystic Fibrosis Conference.

The Phase 3 open-label study included 67 children with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes, including those homozygous for the F508del mutation and those with F508del/minimal function mutations. Treatment with ALYFTREK resulted in a mean reduction in sweat chloride of 9.6 mmol/L from baseline through week 24, with 92% of children achieving concentrations below 60 mmol/L.

Vertex plans to submit for global regulatory approvals of

Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference

Fri, 05 Jun 2026 12:00:00 -0400

- ALYFTREK Phase 3 data on children with cystic fibrosis ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including F/F and F/MF shows 65% reached sweat chloride levels of <30 mmol/L; Vertex on track to initiate global regulatory submissions in first half of 2026 -

- Long-term 96-week interim analyses from two open-label extension studies demonstrate positive safety and efficacy profile of ALYFTREK in people with cystic fibrosis ages 6 and older -

- Phase 3 data on TRIKAFTA® in children 1 to <2 years also presented; Vertex has initiated global regulatory submissions -

BOSTON--(BUSINESS WIRE)--

Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference

Fri, 05 Jun 2026 12:00:00 -0400

- Long-term 96-week interim analyses from two open-label extension studies demonstrate positive safety and efficacy profile of ALYFTREK in people with cystic fibrosis ages 6 and older -

- Phase 3 data on TRIKAFTA® in children 1 to <2 years also presented; Vertex has initiated global regulatory submissions -

BOSTON--(BUSINESS WIRE)--

Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference

Fri, 05 Jun 2026 12:00:00 -0400

- Long-term 96-week interim analyses from two open-label extension studies demonstrate positive safety and efficacy profile of ALYFTREK in people with cystic fibrosis ages 6 and older -

- Phase 3 data on TRIKAFTA® in children 1 to <2 years also presented; Vertex has initiated global regulatory submissions -

BOSTON--(BUSINESS WIRE)--

Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference

Fri, 05 Jun 2026 12:00:00 -0400

- Long-term 96-week interim analyses from two open-label extension studies demonstrate positive safety and efficacy profile of ALYFTREK in people with cystic fibrosis ages 6 and older -

- Phase 3 data on TRIKAFTA® in children 1 to <2 years also presented; Vertex has initiated global regulatory submissions -

BOSTON--(BUSINESS WIRE)--

Form 4 VERTEX PHARMACEUTICALS For: Jun 01 Filed by: Liu Joy

Wed, 03 Jun 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260603/26598817.html

Form 4 VERTEX PHARMACEUTICALS For: Jun 01 Filed by: Liu Joy

Wed, 03 Jun 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260603/26598817.html

Vertex to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 10

Wed, 03 Jun 2026 16:00:00 -0400

BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in the Goldman Sachs 47th Annual Global Healthcare Conference. Dr. Reshma Kewalramani, President and Chief Executive Officer will participate in a fireside chat on Wednesday, June 10, 2026, at 11:20 a.m. ET.

A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com, in the "Investors" section under the "News and Events" page. A replay of the conference webcast will be archived on the company's website.

About Vertex

Vertex is a global biotechnology company that invests in scientific

Vertex to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 10

Wed, 03 Jun 2026 16:00:00 -0400

About Vertex

Vertex is a global biotechnology company that invests in scientific

Vertex to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 10

Wed, 03 Jun 2026 16:00:00 -0400

About Vertex

Vertex is a global biotechnology company that invests in scientific

Vertex to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 10

Wed, 03 Jun 2026 16:00:00 -0400

About Vertex

Vertex is a global biotechnology company that invests in scientific

Form 4 VERTEX PHARMACEUTICALS For: May 29 Filed by: Bozic Carmen

Tue, 02 Jun 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260602/26591477.html

Form 4 VERTEX PHARMACEUTICALS For: May 29 Filed by: Bozic Carmen

Tue, 02 Jun 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260602/26591477.html

Form 144 VERTEX PHARMACEUTICALS Filed by: Liu Joy

Mon, 01 Jun 2026 14:14:00 -0400

si-local-file:///var/storage/secattach/20260601/26582655.html

Form 144 VERTEX PHARMACEUTICALS Filed by: Liu Joy

Mon, 01 Jun 2026 14:14:00 -0400

si-local-file:///var/storage/secattach/20260601/26582655.html

Vertex gets FDA acceptance for IgA nephropathy drug application

Mon, 01 Jun 2026 08:01:18 -0400

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) announced the U.S. Food and Drug Administration has accepted its Biologics License Application for povetacicept, an investigational treatment for adults with immunoglobulin A nephropathy.

The FDA assigned a Prescription Drug User Fee Act target action date of November 30, 2026. The application seeks accelerated approval for povetacicept, which would become Vertex's first commercialized therapy in its nephrology franchise if approved.

The submission is supported by data from a Week 36 interim analysis of the Phase 3 RAINIER trial. Patients treated with povetacicept achieved a 52.0% reduction from baseline in urine protein to creatinine ratio at Week 36,

Vertex gets FDA acceptance for IgA nephropathy drug application

Mon, 01 Jun 2026 08:01:18 -0400

Vertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy

Mon, 01 Jun 2026 08:00:00 -0400

- FDA assigns Prescription Drug User Fee Act (PDUFA) target action date of November 30, 2026 –

BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) submission for povetacicept, an investigational engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in adults with immunoglobulin A nephropathy (IgAN).